HINOON Pharmaceuticals: Major
Health Technology
Mkt Cap
53.5B
P/E (TTM)
13.36
EPS
77.92
ROE
29.09%
Div Yield
4.98%
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 27.71B | 24.64B | 19.77B | 15.82B | 13.00B | |
| Cost of Goods Sold | -13.04B | -12.51B | -10.66B | -7.90B | -6.68B | |
| Gross Profit | 14.67B | 12.13B | 9.10B | 7.92B | 6.32B | |
| SG&A Expenses | -8.22B | -6.90B | -5.59B | -4.59B | -3.91B | |
| Research & Development | -10.79M | -9.47M | -15.02M | -10.63M | -8.67M | |
| Depreciation | -417.78M | -346.67M | -266.07M | -215.83M | -196.92M | |
| Other Operating Expense | -69.09M | -196.11M | -82.42M | -72.72M | -51.59M | |
| Total Operating Expense | -21.33B | -19.61B | -16.34B | -12.56B | -10.65B | |
| Operating Income (EBIT) | 6.38B | 5.03B | 3.43B | 3.25B | 2.36B | |
| Interest Income | 55.49M | 79.39M | 22.11M | 15.13M | 29.15M | |
| Interest Expense | -129.73M | -406.95M | -152.98M | -60.32M | -30.91M | |
| Equity in Earnings | 0 | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | 108.46M | 147.66M | 9.97M | 190.10M | 72.08M | |
| Total Non-Operating Income | 213.72M | -20.79M | -88.89M | 192.27M | 80.58M | |
| Pre-Tax Income | 6.59B | 5.01B | 3.34B | 3.45B | 2.44B | |
| Income Tax | -2.46B | -1.62B | -893.98M | -972.46M | -579.32M | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |
| Net Income | 4.13B | 3.39B | 2.45B | 2.47B | 1.86B | |
| EBITDA | 6.81B | 5.39B | 3.70B | 3.47B | 2.55B | |
| EPS (Basic) | 77.92 | 63.95 | 46.20 | 46.67 | 35.04 | |
| EPS (Diluted) | 77.92 | 63.95 | 46.20 | 46.67 | 35.04 | |
| Gross Margin | 52.94% | 49.23% | 46.06% | 50.08% | 48.59% | |
| Operating Margin | 23.02% | 20.43% | 17.36% | 20.57% | 18.12% | |
| EBITDA Margin | 24.58% | 21.88% | 18.74% | 21.95% | 19.63% | |
| Pre-Tax Margin | 23.79% | 20.34% | 16.91% | 21.78% | 18.74% | |
| Net Margin | 14.90% | 13.75% | 12.38% | 15.63% | 14.28% |